CYC065 is primarily used in research and development within the field of oncology. It functions as a selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK2 and CDK9, which are crucial in regulating cell cycle progression and transcription. By inhibiting these kinases, CYC065 has shown potential in halting the proliferation of cancer cells, making it a promising candidate for cancer therapy. Its application is particularly significant in studies targeting hematologic malignancies and solid tumors, where uncontrolled cell division is a hallmark. Additionally, CYC065 is being explored for its ability to enhance the efficacy of other anticancer agents when used in combination therapies. Research is ongoing to further understand its mechanisms and optimize its use in clinical settings.